Daewoong Pharmaceutical has received a notice of allowance from the U.S. Patent and Trademark Office for ionizable lipid technology used in eTurna, a lipid nanoparticle delivery platform acquired from U.S. biotech firm Turn Biotechnologies. The patent, titled "Lipid Structures and Compositions Containing the Same," covers lipid structures and LNP compositions designed to protect and deliver therapeutic nucleic acids such as mRNA to target cells. Formal registration will follow completion of subsequent procedures. The decision is Daewoong's first global patent achievement since it acquired Turn Bio's cell-reprogramming intellectual property and assets in May and succeeded to the licensor position under Turn Bio's exclusive ERA out-licensing agreement with HanAll Biopharma. ERA uses mRNA-based partial reprogramming to restore aged-cell function while preserving cellular identity. Patent data cited by Daewoong showed increased collagen VII expression and cell proliferation, reduced aging markers and strong cell viability in tests involving human dermal fibroblasts, aged tissue and T cells. The company expects the U.S. rights to strengthen its mRNA therapeutics platform as the technology expands beyond COVID-19 vaccines into cancer and other serious diseases. Precedence Research estimates the global anti-aging therapeutics market will reach about $9.3 billion, or approximately 12.8 trillion won, by 2035, while companies including Altos Labs and Life Biosciences pursue related technologies.